Randomized double-blind study of combination therapy with didanosine and stavudine in HIV-infected individuals

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The combination of two nucleoside analogues, didanosine (2',3'- dideoxyinosine or ddI) and stavudine (2',3'-didehydro-2',3'-dideoxythymidine or d4T) was studied in a double-blind dose-ranging trial to provide information about toxicity and efficacy. The 86 patients studied were antiretroviral naive and had pretreatment CD4 cell counts between 200 and 500 cells/mm3. The combination was well tolerated, with no evidence of dose- related side effects and mini- real development of peripheral neuropathy. There was a sustained decrease in human immunodeficiency virus (HIV) viral RNA levels, which appeared greater in patients receiving a full dose of one or both compounds. A concomitant increase in CD4 cell numbers, which was sustained over 52 weeks of follow-up and which was also dose related, was observed. This combination therapy deserves further study, particularly as part of triple-drug regimens.

Original languageEnglish (US)
Pages (from-to)89-93
Number of pages5
JournalAntiviral Therapy
Volume2
Issue numberSUPPL.3
StatePublished - 1997
Externally publishedYes

Fingerprint

Stavudine
Didanosine
Double-Blind Method
HIV
Viral RNA
Peripheral Nervous System Diseases
CD4 Lymphocyte Count
Nucleosides
Cell Count
Therapeutics
Pharmaceutical Preparations
2',3'-dideoxythymidine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Randomized double-blind study of combination therapy with didanosine and stavudine in HIV-infected individuals. / Pollard, Richard B.

In: Antiviral Therapy, Vol. 2, No. SUPPL.3, 1997, p. 89-93.

Research output: Contribution to journalArticle

@article{767985ed7ba446999def613154f67f99,
title = "Randomized double-blind study of combination therapy with didanosine and stavudine in HIV-infected individuals",
abstract = "The combination of two nucleoside analogues, didanosine (2',3'- dideoxyinosine or ddI) and stavudine (2',3'-didehydro-2',3'-dideoxythymidine or d4T) was studied in a double-blind dose-ranging trial to provide information about toxicity and efficacy. The 86 patients studied were antiretroviral naive and had pretreatment CD4 cell counts between 200 and 500 cells/mm3. The combination was well tolerated, with no evidence of dose- related side effects and mini- real development of peripheral neuropathy. There was a sustained decrease in human immunodeficiency virus (HIV) viral RNA levels, which appeared greater in patients receiving a full dose of one or both compounds. A concomitant increase in CD4 cell numbers, which was sustained over 52 weeks of follow-up and which was also dose related, was observed. This combination therapy deserves further study, particularly as part of triple-drug regimens.",
author = "Pollard, {Richard B}",
year = "1997",
language = "English (US)",
volume = "2",
pages = "89--93",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "SUPPL.3",

}

TY - JOUR

T1 - Randomized double-blind study of combination therapy with didanosine and stavudine in HIV-infected individuals

AU - Pollard, Richard B

PY - 1997

Y1 - 1997

N2 - The combination of two nucleoside analogues, didanosine (2',3'- dideoxyinosine or ddI) and stavudine (2',3'-didehydro-2',3'-dideoxythymidine or d4T) was studied in a double-blind dose-ranging trial to provide information about toxicity and efficacy. The 86 patients studied were antiretroviral naive and had pretreatment CD4 cell counts between 200 and 500 cells/mm3. The combination was well tolerated, with no evidence of dose- related side effects and mini- real development of peripheral neuropathy. There was a sustained decrease in human immunodeficiency virus (HIV) viral RNA levels, which appeared greater in patients receiving a full dose of one or both compounds. A concomitant increase in CD4 cell numbers, which was sustained over 52 weeks of follow-up and which was also dose related, was observed. This combination therapy deserves further study, particularly as part of triple-drug regimens.

AB - The combination of two nucleoside analogues, didanosine (2',3'- dideoxyinosine or ddI) and stavudine (2',3'-didehydro-2',3'-dideoxythymidine or d4T) was studied in a double-blind dose-ranging trial to provide information about toxicity and efficacy. The 86 patients studied were antiretroviral naive and had pretreatment CD4 cell counts between 200 and 500 cells/mm3. The combination was well tolerated, with no evidence of dose- related side effects and mini- real development of peripheral neuropathy. There was a sustained decrease in human immunodeficiency virus (HIV) viral RNA levels, which appeared greater in patients receiving a full dose of one or both compounds. A concomitant increase in CD4 cell numbers, which was sustained over 52 weeks of follow-up and which was also dose related, was observed. This combination therapy deserves further study, particularly as part of triple-drug regimens.

UR - http://www.scopus.com/inward/record.url?scp=6844255875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6844255875&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 89

EP - 93

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - SUPPL.3

ER -